

KENTUCKY BOARD OF PHARMACY

CASE REVIEW MEETING AGENDA

November 22, 2022

9:00 a.m.- 4:00 p.m.

Via VIDEO CONFERENCE

<https://us02web.zoom.us/j/89894819025?pwd=bEk1LzU1bVJwTmQ3T3hQWGwyWkVEZz09>

Meeting ID: 898 9481 9025

Passcode: s3MZHY

One tap mobile

+13017158592,,89894819025#,,,,\*145844# US (Washington DC)

+13092053325,,89894819025#,,,,\*145844# US

Dial by your location

+1 301 715 8592 US (Washington DC)

+1 309 205 3325 US

+1 312 626 6799 US (Chicago)

+1 646 558 8656 US (New York)

+1 646 931 3860 US

+1 564 217 2000 US

+1 669 444 9171 US

+1 669 900 9128 US (San Jose)

+1 689 278 1000 US

+1 719 359 4580 US

+1 253 215 8782 US (Tacoma)

+1 346 248 7799 US (Houston)

+1 360 209 5623 US

+1 386 347 5053 US

+1 507 473 4847 US

Meeting ID: 898 9481 9025

Passcode: 145844

- I. CASE REVIEW MINUTES: October 19, 2022
- II. EXECUTED AGREED ORDERS: October 12- November 13, 2022
  - 22-0636 Kenneth Ukauwa
  - 22-0597 Darrell Homan
  - 22-0626 John Herr
  - 22-0602 Emily Kingery
  - 22-0600 Elizabeth Cherry
  - 22-0518 Kasandra Chambers
  - 22-0657 Richard Van Sant
  - 22-0620 John Crouch
  - 22-0599 Daniel Wermeling
  - 22-0114 Callie Sondergard-Bow
  - 22-0115 C Gary McGuffey

III. CASE EXTENSION REQUESTS:

17-0548 A. P07140 B. 014223  
22-0026 A. P08088 B. 012673  
22-0051 A. P07990 B. 012900 C. 017349  
22-0131 A. P07367 B. 021703  
22-0165 A. P07979 B. 010888  
22-0173 A. P07903 B. 022430  
22-0174 A. P06898 B. 010224 C. PT00358597  
22-0179 A. P02105 B. 011832 C. 018031  
22-0181 017525  
22-0185 A. P07661 B. PT00013404 C. 016498  
22-0186 A. P06181 B. 012632 C. 013836  
22-0187 A. P00579 B. 017980

IV. CASES FOR REVIEW:

22-0002 Revisit A. FL2421 B. 013117  
22-0047 A. P06395 B. 021511 C. 011785  
22-0058 A. P07837 B. 020112 C. 017366  
22-0083 A. P00684 B. 008679 C. 014022 D. 010097 E. 010899 F. 019332  
22-0116 A. P07420 B. 010170 C. 020697 D. PT00348913  
22-0148 A. P01403 B. 018491 C. PT00364843  
22-0155 A. P06027 B. 020736  
22-0163 A. P06315 B. 021488 C. P06588 D. 016099  
22-0164 A. P07219 B. 016736  
22-0171 P06029  
22-0172 A. P07906 B. 015430  
22-0183 007141  
22-0188 A. P07099 B. 013629 C. 022625  
22-0190 021795  
22-0191 A. P02082 B. 019438 C. PT00370569  
22-0192 A. P07100 B. 022117 C. 012388  
22-0197 A. P06903 B. 007180 C. 007653  
22-0198 A. OH1321 B. 019729  
22-0200 A. P06690 B. 022557 C. PT00032698  
22-0202 MG0826  
22-0204 A. P06903 B. 007180  
22-0205 A. P06902 B. 014155 C. PT00377274  
22-0207 015861  
22-0208 A. P07389 B. 022253  
22-0215 A. P08216 B. 021628 C. PT00377064  
22-0218 A. P06903 B. 007180

V. ADJOURN:

*ATTENTION: A portion of the meeting may be held in closed/executive session for the purpose of discussing and deliberating upon open investigations, which are preliminary matters that may result in litigation being filed on behalf of the Board and include the review of information required to be conducted in privacy according to federal and state law (under Agenda Items III and IV). The specific statutory sections providing exemptions are: KRS 61.810(1)(c) KRS 61.878(1)(a) KRS 61.810(1)(j) KRS 61.878(1)(h) KRS 61.810(1)(k). Following discussion and deliberation, any and all action will be taken in open/public session.*